Filtered By:
Source: Neuro-Oncology
Condition: Brain Tumor

This page shows you your search results in order of date.

Order by Relevance | Date

Total 22 results found since Jan 2013.

STMC-26. MULTIVALENT CATIONIC LIPOSOMES FOR siRNA TRANSFECTION OF PATIENT DERIVED GLIOMA INITIATING CELLS
Glioma initiating cells (GICs) have been implicated as the root cause of treatment failure and tumor recurrence in glioblastoma multiforme (GBM). Therapeutic targeting of GICs is therefore essential to ensure effective treatment without relapse. A novel approach to modulate protein expression in cancer cells is the delivery of siRNAs using liposomes. However, past attempts to transfect cells using neutral liposomes have proven challenging and inefficient owing to the highly refractory nature of these cells. We therefore sought to develop a multivalent cationic liposome (MVCL) formulation for efficient and reproducible...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Ravi, V., Madhankumar, A. B. Tags: STEM CELLS Source Type: research

Exth-53. stealth lipid nano-encapsulation enables efficacious therapeutic rna interference in malignant glioma
CONCLUSION:This study establishes a versatile, safe, and efficacious translational strategy for nano-encapsulated RNA interference against GBM, with strong potential for multiplexed lipid nano-siRNA therapeutic actions that impede tumor growth and invasion.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Zhang, P., Yu, D., Han, Y., Wu, M., Lesniak, M. Tags: EXPERIMENTAL THERAPEUTICS - PRECLINICAL STUDIES (NON-IMMUNOLOGICAL) Source Type: research

PDTB-15. Bcl-XL AS A RADIOSENSITIZER IN THE TREATMENT OF GROUP 3 MEDULLOBLASTOMA
Medulloblastoma is the most common malignant pediatric brain tumor. Although significant progress has been made in the treatment of medulloblastoma patients over the past several decades, the five-year disease-free survival for high-risk patients, characterized by metastatic dissemination at presentation or significant post-operative residual tumor, remains relatively poor (25-40%). Group 3 medulloblastoma has by far the worst prognosis with a 5-year survival probability of approximately 30% regardless of stage. Current therapeutic modalities, in particular ionizing radiation (IR), have significant long-term side-effe...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Ruggieri, M., Kelley, K., Powell, C., Navati, M., Chakraborty, S., Wright, A., Remke, M., Friedman, J., Symons, M. Tags: PEDIATRIC TUMORS - PRECLINICAL STUDIES (NON-IMMUNOLOGICAL) Source Type: research

Imst-49. mechanism and therapeutic targeting of osteopontin-mediated immune suppression in gbm
CONCLUSIONS:Osteopontin is an important chemokine to recruit peripheral monocytes to the GBM microenvironment and is essential in mediating crosstalk between tumor cells and the innate immune system.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Wei, J., Marisetty, A., Kong, L.-Y., Gabrusiewicz, K., Hashimoto, Y., Ling, X., Zhou, S., Fuller, G., Heimberger, A. Tags: IMMUNOLOGY - PRECLINICAL STUDIES Source Type: research

CSIG-24. REGULATION OF Fn14 EXPRESSION BY EGFRvIII-STAT SIGNALING ENHANCES GLIOBLASTOMA CELL INVASION AND SURVIVAL
Glioblastoma Multiforme (GBM) is the most common malignant brain tumor in adults. Most GBM patients succumb to the disease less than one-year post diagnosis due to the highly invasive nature of the tumor, which prevents complete surgical resection and gives rise to tumor recurrence. The invasive phenotype also confers radio-and chemoresistant properties to the tumor cells; therefore, there is a need to develop new therapeutics that target drivers of GBM invasion. Amplification of EGFR is observed in over 50% of GBM tumors, of which half concurrently overexpress the variant EGFRvIII, and expression of both receptors confers...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Roos, A., Mayo, Z., Sonnemann, H., Lambert, G., Dhruv, H., Winkles, J., Berens, M., Tran, N., Sabir, M. Tags: CELL SIGNALING AND SIGNALING PATHWAYS Source Type: research

DDIS-06. Ku 70/80 IN GLIOMA - TARGETING WITH APTAMERS
CONCLUSIONS:Certain aptamers appear to readily bind to DNA repair proteins Ku70 and Ku80 and could be used for developing targeted therapy towards glioma. Western and knockdown analysis, confirm the specificity of binding and leads the way for in-vivo testing of aptamers.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Arora, M., Davis, C., Dawson, T., Alder, J., Lawrence, C., Shaw, L. Tags: DRUG DISCOVERY Source Type: research

Exth-05. nanoparticle-mediated inhibition of dna repair increases survival in a genetic after radiotherapy
Radiotherapy is an integral component of the treatment for pediatric and adult brain tumors. However, survival is frequently accompanied by one or more radiation-induced adverse sequelae, especially in children. Therefore, strategies that enhance radiotherapy in brain tumors while sparing adjacent normal brain are expected to improve life-long outcomes. We have developed a nanoparticle delivery vehicle that can stably bind, protect, and deliver nucleic acids to brain cancer cells and tumors. We found that nanoparticle-mediated siRNA delivery reduced expression and activity of the multifunctional DNA repair protein Ape1 spe...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Kievit, F., Wang, K., Ozawa, T., Tarudji, A., Silber, J., Holland, E., Ellenbogen, R., Zhang, M. Tags: EXPERIMENTAL THERAPEUTICS - PRECLINICAL STUDIES (NON-IMMUNOLOGICAL) Source Type: research

P06.20 EGFRvIII: a predictive marker for Temozolomide response in O6-methylguanine-DNA methyltransferase negative glioblastoma cells and tumor xenografts
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults with an estimated 5-year survival of less 10%. The current standard of care involves maximal tumor resection followed by radiation and chemotherapy with the alkylating agent temozolomide (TMZ). Epigenetic silencing of the O6-methylguanine-DNA methyltransferase (MGMT) gene predicts response to TMZ therapy, but does not explain all of the heterogeneity in responses observed in the clinic. The establishment of additional molecular biomarkers, is therefore of significant interest.The aim of the present study was to analyze the impact of endogenous...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Struve, N., Brend, T., Ott, L., Petersen, C., Rothkamm, K., Short, S. C., Kriegs, M. Tags: P06 Biomarkers Source Type: research

P08.67 Inhibition of MutT homolog 1 (MTH1) in glioblastoma multiforme results in impaired cell migration and tumor growth
Discussion:These results show that MTH1 might play an essential role in both, malignization of glioma and disease progression in recurrent glioblastoma. Moreover, the MTH1 level in patients seems to influence tumor growth and could be targeted by crizotinib indicating a role for potential future therapies.
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Timmer, M., Kannampuzha, S. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research

P10.06 Oxamate attenuates aerobic glycolysis, motility, viability and proliferation of medulloblastoma but LDHA siRNA does not
Conclusions:It is possible that oxamate inhibits multiple LDH family members as the active site for LDH isoenzymes, comprised of LDHA and LDHB subunits are identical. The results of further investigations will be critical as LDHA may prove to be an inadequate target for MB and a broader LDH family inhibitor or lactate inhibitor may be more appropriate. However these studies, combined with extensive research into the literature, support the concept and provide proof of principle that targeting aerobic glycolysis and lactate production in medulloblastoma is worthwhile therapeutic avenue worth pursuing further.
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Valvona, C. J., Pilkington, G. J. Tags: P10 Pediatric brain tumours Source Type: research

TR-04 * NANOPARTICLE siRNA DELIVERY VEHICLES INHIBIT DNA REPAIR AND SENSITIZE PEDIATRIC BRAIN TUMOR CELLS TO RADIATION THERAPY
Source: Neuro-Oncology - April 23, 2015 Category: Cancer & Oncology Authors: Kievit, F., Stephen, Z., Wang, K., Dayringer, C., Silber, J., Ellenbogen, R., Zhang, M. Tags: TRANSLATIONAL THERAPEUTICS Source Type: research

VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells
Conclusion Our findings identified VAMP8 as a novel oncogene by promoting cell proliferation and therapeutic resistance in glioma. Targeting VAMP8 may serve as a potential therapeutic regimen for the treatment of glioma.
Source: Neuro-Oncology - February 18, 2015 Category: Cancer & Oncology Authors: Chen, Y., Meng, D., Wang, H., Sun, R., Wang, D., Wang, S., Fan, J., Zhao, Y., Wang, J., Yang, S., Huai, C., Song, X., Qin, R., Xu, T., Yun, D., Hu, L., Yang, J., Zhang, X., Chen, H., Chen, J., Chen, H., Lu, D. Tags: Basic and Translational Investigations Source Type: research

Suppression of miR-184 in malignant gliomas upregulates SND1 and promotes tumor aggressiveness
Conclusions Our study is the first to show a novel regulatory role of SND1, a direct target of miR-184, in glioma progression, suggesting that the miR-184/SND1 axis may be a useful diagnostic and therapeutic tool for malignant glioma.
Source: Neuro-Oncology - February 18, 2015 Category: Cancer & Oncology Authors: Emdad, L., Janjic, A., Alzubi, M. A., Hu, B., Santhekadur, P. K., Menezes, M. E., Shen, X.-N., Das, S. K., Sarkar, D., Fisher, P. B. Tags: Basic and Translational Investigations Source Type: research

Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness
Conclusions This work suggests a possible molecular mechanism of the miR- 326/SMO axis, which can be a potential alternative therapeutic pathway for gliomas.
Source: Neuro-Oncology - January 9, 2015 Category: Cancer & Oncology Authors: Du, W., Liu, X., Chen, L., Dou, Z., Lei, X., Chang, L., Cai, J., Cui, Y., Yang, D., Sun, Y., Li, Y., Jiang, C. Tags: Basic and Translational Investigations Source Type: research

AI-16 * HIF-1a INHIBITION BY RNA INTERFERENCE DELIVERED VIA A NOVEL MULTIFUNCTIONAL SURFACTANT ATTENUATES GLIOMA GROWTH IN AN INTRACRANIAL MOUSE MODEL
CONCLUSIONS: Treating glioblastoma with siRNA targeting HIF-1α in vivo can significantly reduce tumor growth and increase survival in an intracranial mouse model. Our novel siRNA carrier improves delivery of this treatment molecule. With further study this might be extended for use in human patients with malignant gliomas.
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Jensen, R., Gillepsie, D. Tags: ANGIOGENESIS AND INVASION (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research